Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus

Cidofovir (CDV) is one of the most effective antiorthopoxvirus drugs, and it is widely accepted that viral DNA replication is the main target of its activity. In the present study, we report a detailed analysis of CDV effects on the replicative cycles of distinct vaccinia virus (VACV) strains: Cantagalo virus, VACV-IOC, and VACV-WR. We show that despite the approximately 90% inhibition of production of virus progeny, virus DNA accumulation was reduced only 30%, and late gene expression and genome resolution were unaltered. The level of proteolytic cleavage of the major core proteins was diminished in CDV-treated cells. Electron microscopic analysis of virus-infected cells in the presence of CDV revealed reductions as great as 3.5-fold in the number of mature forms of virus particles, along with a 3.2-fold increase in the number of spherical immature particles. A detailed analysis of purified virions recovered from CDV-treated cells demonstrated the accumulation of unprocessed p4a and p4b and nearly 67% inhibition of DNA encapsidation. However, these effects of CDV on virus morphogenesis resulted from a primary effect on virus DNA synthesis, which led to later defects in genome encapsidation and virus assembly. Analysis of virus DNA by atomic force microscopy revealed that viral cytoplasmic DNA synthesized in the presence of CDV had an altered structure, forming aggregates with increased strand overlapping not observed in the absence of the drug. These aberrant DNA aggregations were not encapsidated into virus particles.Vaccinia virus (VACV) is the prototypical member of the Poxviridae, a family of large DNA-containing viruses. During infection, a cascade of temporally regulated viral gene expression occurs exclusively in the cell cytoplasm, where viral DNA replication takes place. DNA replication is essential for the onset of the intermediate and late steps of viral gene expression (37). VACV morphogenesis is a complex process that starts within the virus factories, or virosomes, in parallel with the late stage of gene expression. Crescent-shaped virus membranes evolve into immature spherical particles (IV) that subsequently progress to form brick-shaped mature virions (MV) (reviewed in reference 8). Virus assembly and maturation are complex processes requiring telomere resolution of newly replicated DNA (20, 36, 40), genome encapsidation (6, 22, 50), and the proteolytic processing of major structural proteins (38, 51). For the past decade, several reports have analyzed in detail these numerous steps of VACV morphogenesis, unraveling the role of distinct virus late proteins in the progression of viral particle formation (reviewed in reference 8).Cantagalo virus (CTGV) is a strain of VACV isolated from pustular lesions on cows in Brazil (10). Similar outbreaks of vaccinia-like viruses have been reported frequently over the past 8 years (14, 39, 48). Interestingly, the majority of these vaccinia viruses circulating in the wild in Brazil bear a striking similarity to the Brazilian vaccine strain used for systematic vaccination during the eradication campaign, which was produced in Rio de Janeiro (19) and called strain IOC (10). This similarity raises the interesting possibility that the circulating vaccinia viruses represent feral derivatives of IOC or of a closely related ancestor. Little is known about the sensitivity of these novel vaccinia viruses to antiviral compounds. In the absence of an active smallpox vaccination campaign, the spread of these vaccinia viruses in the wild, the prevalence of cowpox infections in Europe and elsewhere (39), and the occurrence of complications from smallpox vaccination (52) make the need for effective antipoxvirus treatment a worldwide concern.Cidofovir (CDV), an acyclic pyrimidine phosphonate analogue, has shown a potent antiviral effect on several poxvirus infections (4, 15, 44, 46). Recently, we have reported the efficacy of CDV in inhibiting the replication of the Brazilian VACV strains CTGV and IOC (26). The mechanism of action of CDV on reactions catalyzed by the VACV DNA polymerase has been studied in vitro. CDV is not a chain-terminating analogue but drastically slows chain extension and inhibits the 3′-5′ exonuclease proofreading activity of the enzyme (34). In addition, templates containing CDV cause inhibition of DNA elongation (33). Differences between the effects of CDV on human cytomegalovirus (55) and VACV enzymes have been observed, but overall it has been widely accepted that CDV acts by inhibiting the process of virus DNA replication. Moreover, most CDV-resistant VACV strains contain mutations in the catalytic domain or in the 3′-5′ exonuclease domain of the DNA polymerase (2, 5, 28, 45).Despite the consensus regarding mechanisms of action, the effects of CDV on the stages of the VACV replicative cycle have never been analyzed. We report here that although CDV led to approximately 90% inhibition of VACV progeny production, we observed only 30% inhibition of DNA replication and normal levels of postreplicative virus gene expression. However, the encapsidation of DNA into virus particles and the proteolytic processing of the major core proteins were inhibited in CDV-treated cells, leading to an impairment of virus morphogenesis. These effects on virus assembly are an indirect result of a primary effect of CDV on VACV DNA synthesis. Atomic force microscopy (AFM) analysis revealed that virus DNA isolated from the cytoplasm of CDV-treated cells formed aggregates of highly entangled and intertwined DNA molecules that were not observed in cytoplasmic viral DNA isolated from untreated cells. In addition, these DNA aggregates were not detected in encapsidated virus genomes isolated from particles purified from untreated or CDV-treated cells. Our data suggest that incorporation of CDV into VACV DNA during the replication process may lead to aberrant DNA structures, which are less able to be packaged into virus particles.